Showing results (21-30 of 75) with videos related to

Sort By:
Pageof 8
Plos One|October 3, 2012
Patterns of information-seeking for cancer on the internet: an analysis of real world dataYishai Ofran, Ora Paltiel, Dan Pelleg, et al.
Plos One|March 21, 2019
The role of specialized hospital units in infection and mortality risk reduction among patients with hematological cancersRaïsa Carmen, Galit B Yom-Tov, Inneke Van Nieuwenhuyse, et al.
Annals of Hematology|January 7, 2017
Second line azacitidine for elderly or infirmed patients with acute myeloid leukemia (AML) not eligible for allogeneic hematopoietic cell transplantation-a retrospective national multicenter studyRon Ram, Moshe Gatt, Drorit Merkel, et al.
Cancer Immunology, Immunotherapy : CII|September 1, 2022
Compromised activity of natural killer cells in diffuse large b-cell lymphoma is related to lymphoma-induced modification of their surface receptor expressionTehila Azoulay, Ilana Slouzky, Michal Karmona, et al.
Acta Haematologica|March 10, 2024
The Effect of Mind-Body Intervention on Lymphocyte Doubling Time and Treatment-Free Survival in Treatment-Naïve Chronic Lymphocytic Leukemia PatientsShirley Shapira, Naama Hirschberger, Yishai Ofran, et al.
Annals of Hematology|February 21, 2020
Safety and efficacy of blinatumomab: a real world dataArie Apel, Yishai Ofran, Ofir Wolach, et al.
Cell Systems|October 8, 2021
Alignment of single-cell trajectories by tuMap enables high-resolution quantitative comparison of cancer samplesAyelet Alpert, Ornit Nahman, Elina Starosvetsky, et al.
The Journal of Antimicrobial Chemotherapy|July 26, 2015
Mortality burden related to infection with carbapenem-resistant Gram-negative bacteria among haematological cancer patients: a retrospective cohort studyNizar Andria, Oryan Henig, Offer Kotler, et al.
European Journal of Haematology|December 31, 2024
Post-Relapse Outcomes of Older Patients With NPM1-Mutated AML Are Favorable With Allo Transplant in Second RemissionAvraham Frisch, Chezi Ganzel, Yishai Ofran, et al.
British Journal of Haematology|December 25, 2024
CPX-351 +/- gemtuzumab ozogamicin as induction therapy for adult patients with newly diagnosed, favourable-intermediate risk, FLT3-ITD negative, AML: A pilot studyChezi Ganzel, Avraham Frisch, Ofir Wolach, et al.
Pageof 8